Contract research organisation (CRO) Biorasi has selected IBM Watson Health (IBM) as a preferred vendor to expand its capabilities and management in the execution of clinical trials.
Biorasi will expand its capabilities by leveraging IBM’s Clinical Development (ICD) platform, a clinical data management system (CDMS) designed to accelerate the trial process.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Biorasi Data Sciences and Biometrics senior director Roberto Silberwasser said: “The collaboration with IBM Watson Health spotlights our vital business relationship and the innovative capabilities of the ICD solution.
“IBM’s technology solutions not only complement Biorasi’s core competencies as a CRO, but those of other preferred vendors as well.”
The single-instance, fully-integrated, SaaS CDMS ICD means the cycle time to start, amend, and manage clinical studies can be reduced.
Trial sponsors and clinical site staff will be able to centralise and organise information and minimise the time and cost for clinical trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBy serving as a flexible and scalable data management platform, the ICD platform will help design and manage clinical trials by incorporating optional features specific to clinical trials.
A previous clinical study revealed that Biorasi could reduce the database build time by 25% and overall project costs by more than half by leveraging ICD’s capabilities.
IBM Watson Health Life Sciences vice-president Mary Varghese Presti said: “We are moving into a new era of clinical development as the Covid-19 crisis has reinforced the desperate need to find meaningful ways to help accelerate the clinical trial process.
“We are proud to support Biorasi’s ongoing effort to bring greater efficiency and precision to the clinical trial process, particularly in emerging areas such as digital therapeutics, virtual trials and rescue studies.”
